ArticleScience advances2021
Massive clonal expansion of polycytotoxic skin and blood CD8
Abstract read
In one paragraph
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System.Frontiers in allergy · 2022Pooled it
- In Vitro Monitoring of Human T Cell Responses to Skin Sensitizing Chemicals-A Systematic Review.Cells · 2021Pooled it
- Combined immune modulation reveals carbamazepine-associated CD8Archives of toxicology · 2026Article
- Neurovascular coupling in the basolateral amygdala modulates negative emotions.Cell research · 2026Article
- Involvement of B Cell Subsets in Patients With Steven Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).Allergy · 2026Article
- Omeprazole activation of CD4+ and CD8+ T-cells through off-target covalent modification of cellular proteins.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Carbamazepine activates private self and viral reactive TCRs through a drug-permissive HLA-B cleft.Frontiers in immunology · 2026Article
- Immunological and molecular signatures of carbamazepine-induced maculopapular exanthema.Frontiers in immunology · 2026Article
- Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology.Allergy · 2025Review
- Oral Cyclosporine Treatment for Four Pediatric Patients With Toxic Epidermal Necrolysis That Showed No Response to High-dose Corticosteroids in Combination With Intravenous Immunoglobulin: A Case Series.Current therapeutic research, clinical and experimental · 2025Article
- Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade.Nature communications · 2024Article
- Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.American journal of clinical dermatology · 2024Review
- Stevens-Johnson syndrome-toxic epidermal necrolysis overlap in a patient taking quetiapine and famotidine: a case report.Journal of medical case reports · 2024Article
- Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis.Toxicological sciences : an official journal of the Society of Toxicology · 2024Review
- Toxic Epidermal Necrolysis Caused by Eribulin.Cureus · 2024Article
- Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024Review
- Single-cell mass cytometry in immunological skin diseases.Frontiers in immunology · 2024Review
- Functional heterogeneity of human skin-resident memory T cells in health and disease.Immunological reviews · 2023Review
- Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.The Journal of allergy and clinical immunology · 2023Review
- Why drug exposure is frequently associated with T-cell mediated cutaneous hypersensitivity reactions.Frontiers in toxicology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Axel Patrice VillaniCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0002-3067-807X
Aurore RozieresCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0003-0293-4002
Benoît BensaidDrug Allergy Reference Center, Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Dermatologie, Lyon, France.
Klara Kristin ErikssonDepartment of Rheumatology, Immunology and Allergology, Drug Allergy Research Laboratory, University Hospital of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-2560-9221
Amandine MosnierCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0002-7300-8359
Floriane AlbertCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Virginie MutezCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Océane BrassardCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Tugba BaysalCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Mathilde TardieuCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Omran AllatifCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0002-2539-972X
Floriane FusilCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Thibault AndrieuCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0001-6055-1910
Denis JullienCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0002-2995-7928
Valérie DuboisEtablissement Français du Sang (EFS), Décines, France.ORCID 0000-0002-1169-7697
Catherine GiannoliEtablissement Français du Sang (EFS), Décines, France.
Henri GruffatCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0002-4735-6894
Marc PallardyINSERM, UMR 996, Châtenay-Mallabry, France.
François-Loïc CossetCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Audrey NosbaumCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.
Osami KanagawaCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0001-6028-7742
Janet L MaryanskiUnité de Thérapie Cellulaire et Génique (UTCG), Centre Hospitalier Universitaire de Nice, 06101 Nice, France.
Daniel YerlyDepartment of Rheumatology, Immunology and Allergology, Drug Allergy Research Laboratory, University Hospital of Bern, 3010 Bern, Switzerland.ORCID 0000-0003-2857-0737
Jean-François NicolasCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France.ORCID 0000-0003-4204-803X
Marc VocansonCentre International de Recherche en Infectiologie (CIRI); INSERM, U1111; Université de Lyon 1; Ecole Normale Supérieure de Lyon; and CNRS, UMR 5308, Lyon, France. marc.vocanson@inserm.fr.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxic epidermal necrolysis (TEN) is a life-threatening cutaneous adverse drug reaction. To better understand why skin symptoms are so severe, we conducted a prospective immunophenotyping study on skin and blood. Mass cytometry results confirmed that effector memory polycytotoxic CD8
Indexed as
Stevens-Johnson SyndromeCD8-Positive T-LymphocytesClone CellsHumansImmunophenotypingProspective StudiesReceptors, Antigen, T-CellReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.